Treatment efficacy and patient satisfaction of ustekinumab compared with tumor necrosis factor-alpha inhibitors in Chinese patients with moderate-to-severe psoriasis: a real-world study

• मुख्य लेखकों: Bin Guo (लेखक), Xiaobo Jin (लेखक), Leiqiang Fan (लेखक), Yanfeng Zhang (लेखक), Bing Xu (लेखक), Tao Yang (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Background Ustekinumab is an interleukin (IL)-12/IL-23 inhibitor for the treatment of moderate-to-severe psoriasis.Objective This real-world study compared ustekinumab and tumor necrosis factor-alpha inhibitors (TNFis) in Chinese moderate-to-severe psoriasis patients.Methods Patient health records o...